Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for CervoMed (CRVO) over the last 10 years, with Q3 2025 value amounting to $30.6 million.

  • CervoMed's Liabilities and Shareholders Equity fell 3738.06% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.4 million, marking a year-over-year increase of 2524.63%. This contributed to the annual value of $43.1 million for FY2024, which is 33200.32% up from last year.
  • Per CervoMed's latest filing, its Liabilities and Shareholders Equity stood at $30.6 million for Q3 2025, which was down 3738.06% from $38.1 million recorded in Q2 2025.
  • In the past 5 years, CervoMed's Liabilities and Shareholders Equity ranged from a high of $53.2 million in Q2 2024 and a low of $3.4 million during Q2 2023
  • Its 4-year average for Liabilities and Shareholders Equity is $25.5 million, with a median of $29.2 million in 2022.
  • Per our database at Business Quant, CervoMed's Liabilities and Shareholders Equity plummeted by 8847.24% in 2023 and then surged by 148107.12% in 2024.
  • Over the past 4 years, CervoMed's Liabilities and Shareholders Equity (Quarter) stood at $4.2 million in 2022, then skyrocketed by 139.86% to $10.0 million in 2023, then soared by 332.0% to $43.1 million in 2024, then dropped by 28.95% to $30.6 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $30.6 million for Q3 2025, versus $38.1 million for Q2 2025 and $38.6 million for Q1 2025.